RxDoctor Payments Data

Maria Gonzalez, PA

Physician Assistant · Venice, FLNPI 1407168289

Payments from drug & device makers

$860in general payments, 2019–2025

Across 17 payments — averaging $50.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$313
  • AstraZeneca$246
  • Convatec Inc.$138
  • Bayer$122
  • Novo Nordisk$22
  • Pfizer$20

What the payments were for

  • Food & beverage$860100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK6$313
AstraZeneca2$246
Convatec Inc.2$138
Bayer5$122
Novo Nordisk1$22
Pfizer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$860 in reported general payments places this provider in the 60th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$146,999
Medicare patients
1,055
Services billed
4,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lagevrio (Eua)Molnupiravir13$9,570
Albuterol Sulfate HfaAlbuterol Sulfate193$3,422
Doxycycline Hyclate408$3,092
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort42$2,234
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav213$1,536
PaxlovidNirmatrelvir/Ritonavir21$1,413
Fluticasone Propionate131$1,138
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst89$881
Wixela InhubFluticasone Propion/Salmeterol11$808
Prednisone432$586
Ciprofloxacin Hcl71$513
Azithromycin151$461
ValacyclovirValacyclovir Hcl20$453
Cephalexin65$443
Oseltamivir Phosphate17$417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$20$1,41321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →